Briteseed, LLC Competitors

Kaiser Permanente's Division of Research (DOR) is one of the nation’s largest research facilities outside of a government or university setting. Our studies cover a wide range of clinical topics, including cardiovascular disease, cancer, diabetes, substance abuse, mental health, maternal and child health, and women’s health. Our research addresses broad issues, including the role of genes and the environment in health, the influence of behavior on disease prevention and chronic illness management, drug safety, health care policy, health services delivery, and disparities. The Division is currently home to 75 research scientists and staff scientists, 17 research fellows, and more than 674 employees. The DOR also has 46 adjunct investigators from within Kaiser Permanente Northern California (KPNC) and other academic institutions. DOR’s scientists are involved in 612 ongoing research projects and the KPNC Clinical Trials Program supports and guides 326 active clinical trials following 3,917 members. Since 2000, DOR researchers have published more than 8,100 peer-reviewed articles, and across all KPNC researchers there were more than 1,000 papers published in 2025 alone.

Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, a wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California. We’re hiring! Join us at hingehealth.com/careers

For 15 years, Omada Health has been in the corner of millions of Americans managing chronic conditions. We help our members between doctor visits, providing virtual care that adapts to real life. We partner with employers, health plans, pharmacy benefit managers, and government agencies to support their populations across common chronic conditions — from prediabetes, diabetes, and hypertension to muscle and joint pain— all through the convenience of an app. Our programs also adapt to provide specialized care for GLP-1 journeys. At Omada, care isn’t built for perfection. It’s built for real people. Our clinically-validated programs combine human connection with modern technology, pairing members with real coaches and care teams. Omada’s impact is proven: our outcomes are published in 30 peer-reviewed studies, showing lasting behavior change, reduced healthcare costs, and ROI for our partners. Our success starts with our people. Omada’s strong, inclusive culture has earned us the Great Place to Work certification, and in 2025 we became a Nasdaq-listed company — a milestone on our mission to bend the curve of chronic disease.